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Abstract
Background: Primary Non Hodgkin's Lymphoma (NHL) of the lacrimal sac is rare.
Methods: The clinical features of a 78 year old female who presented with epiphora and swelling
of the left lacrimal sac are described.
Results:  Computerised tomography showed a mass involving the left lacrimal sac.
Histopathological examination revealed a diffuse large B cell NHL. Immunohistological examination
demonstrated B cell origin. Chemotherapy could not be administered due to co morbid conditions.
The patient was treated with radiotherapy to a dose of 45 Gy in 25 fractions. Patient is disease free
and on follow up after 36 months.
Conclusion: Primary radiotherapy is a treatment option with curative potential for localized NHL
of the lacrimal sac and may be considered in patients who cannot tolerate appropriate
chemotherapy.
Background
Tumors involving the nasolacrimal drainage system are
rare and more than 90% of these tumours are of epithelial
origin [1]. Majority of lymphomas involving the lacrimal
sac are secondary to systemic lymphoreticular malignancy
[1]. Primary non Hodgkin's lymphoma (NHL) of the lac-
rimal sac is a rare neoplasm [2-6]. Therefore, the clinico-
pathological features and optimal management of
primary lacrimal sac NHL are not well characterized.
In this report, we present the clinical features of a patient
with primary NHL of the lacrimal sac treated successfully
with radiotherapy.
Case presentation
A 78 year old female patient presented with epiphora of
the left eye of 6 months duration and a painless swelling
of the left lacrimal sac area of 2 months duration. Physical
examination showed a firm, non-tender mass measuring
3 × 4 cm in the right lacrimal fossa. Irrigation test revealed
complete obstruction of the lacrimal drainage system.
Rest of the eye and adnexae were normal. Computerised
tomography (CT) scan of the orbit showed a heterogene-
ous soft tissue mass arising from the lacrimal sac, infiltrat-
ing and pushing the globe laterally and forward, causing
exophthalmos with no bony erosion (figure 1). There was
homogenous and intense enhancement with contrast.
An incision biopsy was performed from the mass and
pathological examination of revealed diffuse large cell
lymphoma. Immunohistochemistry demonstrated malig-
nant clonal cells of B cell origin (CD20 positive), lacking
T cell antigens. Physical examination, biochemical tests,
CT scan of the chest and abdomen, and bone marrow
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biopsy did not show evidence of lymphomatous involve-
ment elsewhere. The patient had diffuse large B cell Non
Hodgkin's lymphoma of the right lacrimal sac, stage IE by
the Ann Arbor staging system and IPI score of 2 (low inter-
mediate).
The patient was treated with radiotherapy to a dose of 45
Gy in 25 fractions over 5 weeks by three dimensional con-
formal lens sparing technique. Systemic chemotherapy
was not proposed in view of the advanced age of the
patient, poor performance status and concurrent co mor-
bidities. The patient continues to be on follow up after 36
months with no evidence of local or systemic recurrence
and preservation of visual acuity.
Discussion
Primary lymphoma of the lacrimal sac is rare, with most
reported cases representing secondary involvement from
systemic lymphoproliferative malignancy [1]. Only 16 of
212 lacrimal sac tumors described by Flanagan and Stokes
were lymphoreticular tumors [1]. In largest cumulative
series of nonepithelial tumors of the lacrimal sac, Pe'er at
al found that 8 of 35 cases were primary lymphoma [2].
The typical presentation of a lacrimal sac tumour is as a
medial canthal swelling with nasolacrimal duct obstruc-
tion. The differentials for a lacrimal sac mass include non-
granulomatous inflammation and granulomatous
infections, dermoid cyst, mucocele, lipoma, lymphangi-
oma and tumors of the lacrimal duct like adenocarci-
noma, squamous cell carcinoma, adenoid cystic
carcinoma, hemangiomas, sarcomas, melanoma, lym-
phoma and secondaries.
Nasolacrimal sac tumors may arise within the sac or from
structures surrounding the sac or duct. In previous reports
of primary NHL of the lacrimal sac, Jordan and Nerad [7]
observed a lacrimal sac mass extending into the nasolac-
rimal duct, Saccogna et al [8] demonstrated CT findings of
a large mass involving the nasolacrimal duct area and the
adjacent paranasal sinuses and Erickson et al [9] treated
several patients with lymphomatous infiltration of the
nasolacrimal canal.
The vast majority of NHLs of the orbit and ocular adnexa
are of B cell origin. T cell lesions are rare and usually are
associated with disseminated cutaneous lymphomas,
such as mycosis fungoides, Sézary syndrome, or adult T
cell leukemia. Primary lacrimal sac lymphoma also
appears to be commonly of B cell origin and the usual
subtypes are either indolent types like MALT lymphoma
or extranodal marginal B cell lymphoma or aggressive
subtypes like diffuse large B cell lymphoma [7].
The treatment of lacrimal sac tumors of epithelial origin is
mainly surgical. However, in cases of orbital lymphoma
extensive surgery is to be avoided for adequate cosmesis
and functional preservation of the eye [9-14].
Chemotherapy is considered the standard treatment for
localized aggressive NHL with either CHOP based chem-
otherapy alone or limited cycles of chemotherapy fol-
lowed by a lower dose of involved field radiotherapy after
a good response [15]. Chemotherapy alone as primary
treatment for Stage I orbital lymphomas has not been
proven and is not advocated except for patients with
advanced disease of aggressive histology [10,14,16,17]. A
combination of short course chemotherapy and radio-
therapy offers optimum cure rates with lower toxicity in
these tumors [15]. Survival rates have improved with the
addition of Rituximab to CHOP chemotherapy and fur-
ther studies investigating the benefits of adding mono-
clonal antibodies to chemotherapy and radiotherapy are
ongoing [18].
Radiotherapy which is considered the standard treatment
for indolent orbital lymphomas, has also been found to
be successful in aggressive NHL in some reports [5,13,14].
The doses recommended vary according to the site and
histology of NHL, with no clear dose response yet evident
[12-14]. In view of the fact that the prognosis of lacrimal
sac lymphoma is good, radiation doses of 30 – 45 Gy may
be recommended for these localized lesions with limited
long term morbidity [13,14].
Computerised Tomograph of the orbit showing the lacrimal  sac tumour with contrast enhancement Figure 1
Computerised Tomograph of the orbit showing the lacrimal 
sac tumour with contrast enhancement.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
World Journal of Surgical Oncology 2007, 5:127 http://www.wjso.com/content/5/1/127
Page 3 of 3
(page number not for citation purposes)
Conclusion
The present result suggests that radial radiotherapy alone
may be a treatment option with curative potential for pri-
mary localized NHL of the lacrimal sac and may be con-
sidered in patients who cannot tolerate appropriate
chemotherapy.
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